8-K: Alumis SLE Trial Misses Overall Endpoints, Focuses on Subgroup

Alumis Inc. announced that its Phase 2b LUMUS trial for envudeucitinib in Systemic Lupus Erythematosus (SLE) did not meet its primary and secondary endpoints in the overall patient population, though a specific subgroup showed robust responses.

Summary

• Alumis Inc. announced topline results from its Phase 2b LUMUS trial of envudeucitinib for moderate-to-severe Systemic Lupus Erythematosus (SLE).
• The trial did not meet its primary and secondary endpoints in the overall patient population.
• However, a prespecified subgroup of patients with a high interferon gene signature (IFNGS-high) demonstrated robust clinical responses.
• These IFNGS-high patients represent the majority of moderate-to-severe SLE cases and typically respond better to interferon pathway-targeted therapies.
• Envudeucitinib was generally well-tolerated with no new safety signals observed.
• The company plans to engage with regulators to discuss Phase 3 development for envudeucitinib in SLE, focusing on the IFNGS-high subgroup.
• Alumis remains on track to submit a New Drug Application (NDA) for envudeucitinib in moderate-to-severe plaque psoriasis in the fourth quarter of 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed result. While the drug did not meet primary endpoints in the overall population for SLE, the robust response in a specific subgroup (IFNGS-high) provides a potential path forward, but introduces complexity and uncertainty.

Positives

• Robust clinical responses were observed in the prespecified subgroup of patients with a high interferon gene signature (IFNGS-high) across primary and key secondary endpoints.
• Pharmacodynamic data confirmed dose-dependent interferon-pathway target engagement, supporting the drug's mechanism of action.
• Envudeucitinib demonstrated a favorable safety profile with no new safety signals observed in the trial.
• The company plans to use these insights to inform Phase 3 development and engage with regulatory authorities.
• Alumis is on track to submit an NDA for envudeucitinib in plaque psoriasis in Q4 2026.

Negatives

• The Phase 2b LUMUS trial did not meet its primary and secondary endpoints in the overall patient population.
• A higher-than-expected proportion of patients with a low interferon gene signature (IFNGS-low) in the trial contributed to lower overall efficacy outcomes.
• The IFNGS-low subgroup showed less favorable responses to the treatment.

Risks

• The trial's failure to meet overall endpoints introduces uncertainty regarding regulatory approval for SLE.
• The reliance on a specific subgroup (IFNGS-high) for future development may complicate trial design and patient selection.
• The potential for lower-than-expected placebo response rates in the IFNGS-high subgroup needs careful management in Phase 3.
• Competition from other TYK2 inhibitors and existing SLE treatments poses a market risk.
• The company's ability to secure sufficient funding for Phase 3 development and commercialization remains a factor.

Future Outlook

Alumis plans to submit an NDA for envudeucitinib in moderate-to-severe plaque psoriasis in Q4 2026. The company will engage with regulatory authorities to discuss Phase 3 development for envudeucitinib in SLE, focusing on the IFNGS-high subgroup. They are also evaluating opportunities to maximize the value of their TYK2 portfolio and exploring potential multi-indication opportunities for envudeucitinib in interferon-driven diseases.

Management Comments

• "Although envudeucitinib did not meet its primary objective in the overall trial population, the magnitude of effect observed in the prespecified IFNGS-high subgroup is highly compelling in a disease with no targeted oral therapies currently available. We plan to engage regulators to discuss Phase 3 development for envudeucitinib."
• "The mechanism validated by these data underscores a multi-indication opportunity for envudeucitinib across Type I interferon-driven diseases, including cutaneous lupus erythematosus and Sjgrens disease. We are actively evaluating opportunities to maximize the value of our oral TYK2 portfolio and remain on track to file an NDA for envudeucitinib in moderate-to-severe plaque psoriasis in the fourth quarter of this year."

Industry Context

StockSavvy.ai notes that the results highlight the increasing importance of patient stratification in clinical trials for complex autoimmune diseases like SLE. The success of targeted therapies often hinges on identifying specific patient subgroups that are more likely to respond, as demonstrated by the IFNGS-high subgroup in this trial. This approach is becoming a standard in biopharmaceutical development.

Comparison to Industry Standards

• The LUMUS trial's IFNGS-high subgroup results are compared to other TYK2 inhibitors (Deucravacitinib) and Type I interferon inhibitors (Anifrolumab) in SLE. In the IFNGS-high subgroup, envudeucitinib showed competitive BICLA response rates (e.g., 52.6% for 40mg BID vs. placebo 28.6%) and SRI-4 response rates (e.g., 60.9% for 40mg BID vs. placebo 33.1%).
• Cross-trial comparisons indicate that envudeucitinib's performance in the IFNGS-high subgroup is comparable to or potentially better than other agents in similar patient populations, though direct head-to-head comparisons are not available due to differences in trial designs, populations, and assays.

Stakeholder Impact

• Shareholders may react negatively to the failure to meet overall trial endpoints, despite positive subgroup data, potentially impacting stock price.
• Patients with SLE may see a delayed or more complex path to a new treatment option if Phase 3 development is challenging.
• Healthcare providers will need to consider the implications of subgroup analysis for future treatment decisions and patient selection.

Next Steps

• Engage with regulators (FDA and EMA) to discuss Phase 3 development for envudeucitinib in SLE.
• Incorporate learnings from LUMUS into Phase 3 trial design and sizing.
• Confirm Phase 3 dose and define enrollment criteria related to IFNGS status.
• Further characterize the responder population using biomarkers.
• Continue ongoing partnering discussions.
• Submit NDA for envudeucitinib in moderate-to-severe plaque psoriasis in Q4 2026.

Key Dates

Recommendation

The mixed results from the LUMUS trial warrant a 'hold' recommendation. While the failure to meet overall endpoints is a significant negative, the robust response in the IFNGS-high subgroup offers a potential path forward and maintains some value. The company's ongoing development in psoriasis and the potential for further SLE development based on subgroup data create a complex risk/reward profile that is not yet a clear buy or sell.

Keywords

envudeucitinib, Systemic Lupus Erythematosus, SLE, LUMUS trial, TYK2 inhibitor, interferon gene signature, biopharmaceutical, clinical trial results